A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer

Publication date: 9 October 2017
Source:Cancer Cell, Volume 32, Issue 4
Author(s): Stephano S. Mello, Liz J. Valente, Nitin Raj, Jose A. Seoane, Brittany M. Flowers, Jacob McClendon, Kathryn T. Bieging-Rolett, Jonghyeob Lee, Danton Ivanochko, Margaret M. Kozak, Daniel T. Chang, Teri A. Longacre, Albert C. Koong, Cheryl H. Arrowsmith, Seung K. Kim, Hannes Vogel, Laura D. Wood, Ralph H. Hruban, Christina Curtis, Laura D. Attardi
The p53 transcription factor is a critical barrier to pancreatic cancer progression. To unravel mechanisms of p53-mediated tumor suppression, which have remained elusive, we analyzed pancreatic cancer development in mice expressing p53 transcriptional activation domain (TAD) mutants. Surprisingly, the p53^53,54 TAD2 mutant behaves as a "super-tumor suppressor," with an enhanced capacity to both suppress pancreatic cancer and transactivate select p53 target genes, including Ptpn14. Ptpn14 encodes a negative regulator of the Yap oncoprotein and is necessary and sufficient for pancreatic cancer suppression, like p53. We show that p53 deficiency promotes Yap signaling and that PTPN14 and TP53 mutations are mutually exclusive in human cancers. These studies uncover a p53-Ptpn14-Yap pathway that is integral to p53-mediated tumor suppression.

Graphical abstract

Teaser

Mello et al. find that a p53 mutant harboring mutations in the second transcriptional activation domain has enhanced tumor suppression capacities due to hyperactivation of the p53 target gene Ptpn14. Ptpn14 suppresses Yap activity and is required for p53 tumor suppressor activity in pancreatic cancer.


http://ift.tt/2y8G7O1